Q-omics provides the consensus-scored CCNYL5 profile across patient tissues and cancer cell-line models. CCNYL5 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, CCNYL5 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, CCNYL5 RNA expression shows 6,378 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LUAD as cancer lineages where CCNYL5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCNYL5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCNYL5 survival associations across molecular data types. CCNYL5 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCNYL5 RNA expression–survival associations across cancer types. High CCNYL5 expression shows unfavorable associations in STAD, LAML, TGCT and LUAD, but favorable associations in HNSC and PRAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for CCNYL5 RNA expression.
This table summarizes CCNYL5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCNYL5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCNYL5 shows lower tumor expression in KICH and higher tumor expression in LUAD, LUSC and KIRC. The LUAD box plot shows higher CCNYL5 RNA expression in tumor versus normal tissue (log2 FC = +0.113, t-test p = .019).
This table shows molecular features associated with CCNYL5 in patient tissues and cancer cell lines. In patient samples, CCNYL5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
